A Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation
Belatacept, a CTLA4-Ig, was designed to prevent rejection and graft loss in kidney transplant recipients. This immunotherapy showed a long-term clinical benefit mainly on renal function and better glycemic control but was also associated with a higher number of severe infectious diseases, particularly CMV disease, and lymphoproliferative disease. Therapeutic drug monitoring usually guides the benefit-risk assessment of long-term immunosuppression. In this study, an analytical method by LC-MS/MS was developed in 20 microL of plasma for the belatacept quantification. Intra- and inter-assay precision and accuracy were lower than 20% for the limit of quantification, and 15% for higher concentrations. The method was implemented in our lab and provided data about the inter-variability (N = 108) and intra-variability (N = 33) of belatacept concentrations in kidney transplant recipients with a stable renal function, after conversion from a CNI- to a belatacept-based regimen.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Biomedicines - 11(2023), 11 vom: 01. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chhun, Stéphanie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Belatacept |
|---|
| Anmerkungen: |
Date Revised 28.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/biomedicines11112955 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364931736 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364931736 | ||
| 003 | DE-627 | ||
| 005 | 20231226100608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines11112955 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM364931736 | ||
| 035 | |a (NLM)38001955 | ||
| 035 | |a (PII)2955 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chhun, Stéphanie |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Validated LC-MS/MS Method for Performing Belatacept Drug Monitoring in Renal Transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Belatacept, a CTLA4-Ig, was designed to prevent rejection and graft loss in kidney transplant recipients. This immunotherapy showed a long-term clinical benefit mainly on renal function and better glycemic control but was also associated with a higher number of severe infectious diseases, particularly CMV disease, and lymphoproliferative disease. Therapeutic drug monitoring usually guides the benefit-risk assessment of long-term immunosuppression. In this study, an analytical method by LC-MS/MS was developed in 20 microL of plasma for the belatacept quantification. Intra- and inter-assay precision and accuracy were lower than 20% for the limit of quantification, and 15% for higher concentrations. The method was implemented in our lab and provided data about the inter-variability (N = 108) and intra-variability (N = 33) of belatacept concentrations in kidney transplant recipients with a stable renal function, after conversion from a CNI- to a belatacept-based regimen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTLA4-Ig | |
| 650 | 4 | |a belatacept | |
| 650 | 4 | |a kidney | |
| 650 | 4 | |a pharmacokinetic | |
| 650 | 4 | |a transplantation | |
| 700 | 1 | |a Trauchessec, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Melicine, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Miele, Agathe |e verfasserin |4 aut | |
| 700 | 1 | |a Lukic, Srboljub |e verfasserin |4 aut | |
| 700 | 1 | |a Vilain, Estelle |e verfasserin |4 aut | |
| 700 | 1 | |a Amrouche, Lucile |e verfasserin |4 aut | |
| 700 | 1 | |a Lebert, Dorothée |e verfasserin |4 aut | |
| 700 | 1 | |a Anglicheau, Dany |e verfasserin |4 aut | |
| 700 | 1 | |a Tartour, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Zuber, Julien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 11(2023), 11 vom: 01. Nov. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:11 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines11112955 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 11 |b 01 |c 11 | ||